RBC puts Boston Scientific at sector perform

Boston Scientific Corp. was given a sector perform, above average risk, rating from RBC Capital Markets analyst Phil Nalbone after the company finally held its much-anticipated analyst meeting. The company's 2007 sales guidance was not that helpful, according to Nalbone, due to the extremely wide range ($8.65 billion to $9.45 billion). RBC lowered its fourth-quarter revenue estimate by about $100 million to $2.05 billion (+33.3%), and full-year sales estimates to $7.81 billion (+24.3%), also down $100 million. Shares of the Natick, Mass.-based medical device company were down 25 cents, or 1.48%, at $16.64. (NYSE: BSX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.